These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 37450611)

  • 1. Interface policies bridging outpatient and hospital sectors in Europe: can cross-sectorial collaboration in reimbursement and procurement improve access to affordable medicines?
    Vogler S; Salcher-Konrad M; Habimana K
    Expert Rev Pharmacoecon Outcomes Res; 2023; 23(8):867-878. PubMed ID: 37450611
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new approach to gathering pharmaceutical market data to support policy implementation and access to medicines: as demonstrated by malaria medicines in Zambia.
    Coghlan R; Stephens P; Mwale B; Siyanga M
    Malar J; 2018 Nov; 17(1):444. PubMed ID: 30497504
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Access to affordable medicines after health reform: evidence from two cross-sectional surveys in Shaanxi Province, western China.
    Fang Y; Wagner AK; Yang S; Jiang M; Zhang F; Ross-Degnan D
    Lancet Glob Health; 2013 Oct; 1(4):e227-37. PubMed ID: 25104348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Access and Affordability of Medicines in Malaysia: Need for a National Pricing Policy.
    Wong SL; Ibrahim S; Abdul Kadir N; Mohd Salleh S
    Appl Health Econ Health Policy; 2019 Oct; 17(5):641-654. PubMed ID: 31093937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pricing, Procurement and Reimbursement Policies for Incentivizing Market Entry of Novel Antibiotics and Diagnostics: Learnings from 10 Countries Globally.
    Vogler S; Habimana K; Haasis MA; Fischer S
    Appl Health Econ Health Policy; 2024 Sep; 22(5):629-652. PubMed ID: 38837100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disclosure, transparency, and accountability: a qualitative survey of public sector pharmaceutical committee conflict of interest policies in the World Health Organization South-East Asia Region.
    Grundy Q; Parker L; Wong A; Fusire T; Dimancesco D; Tisocki K; Walkowiak H; Vian T; Kohler J
    Global Health; 2022 Mar; 18(1):33. PubMed ID: 35303902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How well does Malaysia achieve value for money in public sector purchasing of medicines? Evidence from medicines procurement prices from 2010 to 2014.
    Hamzah NM; Perera PN; Rannan-Eliya RP
    BMC Health Serv Res; 2020 Jun; 20(1):509. PubMed ID: 32503539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A review of promoting access to medicines in China - problems and recommendations.
    Sun J; Hu CJ; Stuntz M; Hogerzeil H; Liu Y
    BMC Health Serv Res; 2018 Feb; 18(1):125. PubMed ID: 29458428
    [TBL] [Abstract][Full Text] [Related]  

  • 10. How to solve financing gap to ensure patient access to patented pharmaceuticals in CEE countries? - the good, the bad, and the ugly ways.
    Inotai A; Kaló Z
    Expert Rev Pharmacoecon Outcomes Res; 2019 Dec; 19(6):627-632. PubMed ID: 31810392
    [No Abstract]   [Full Text] [Related]  

  • 11. Personalised medicine as a challenge for public pricing and reimbursement authorities – A survey among 27 European countries on the example of trastuzumab.
    Leopold C; Vogler S; Habl C; Mantel-Teeuwisse AK; Espin J
    Health Policy; 2013 Dec; 113(3):313-22. PubMed ID: 24409503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relationship between pharmaceutical pricing strategies with price, availability, and affordability of cardiovascular disease medicines: surveys in Qatar and Lebanon.
    Abdel Rida N; Mohamed Ibrahim MI; Babar ZUD
    BMC Health Serv Res; 2019 Dec; 19(1):973. PubMed ID: 31852546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmaceutical procurement among public sector procurers in CARICOM.
    Preston C; King C; Hinds M; Burnett F; Extavour RM
    Rev Panam Salud Publica; 2021; 45():e57. PubMed ID: 34025728
    [TBL] [Abstract][Full Text] [Related]  

  • 14. "Ready for the future?" - Status of national and cross-country horizon scanning systems for medicines in European countries.
    Vogler S
    Ger Med Sci; 2022; 20():Doc05. PubMed ID: 35465640
    [No Abstract]   [Full Text] [Related]  

  • 15. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Funding and Service Organization to Achieve Universal Health Coverage for Medicines: An Economic Evaluation of the Best Investment and Service Organization for the Brazilian Scenario.
    Garcia MM; Azevedo PS; Mirelman A; Safatle LP; Iunes R; Bennie MC; Godman B; Guerra Junior AA
    Front Pharmacol; 2020; 11():370. PubMed ID: 32351382
    [TBL] [Abstract][Full Text] [Related]  

  • 17.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 18.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 16.